Better Therapeutics - BTTX Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $6.00
  • Forecasted Upside: 57,042.86%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$0.01
+0 (0.00%)

This chart shows the closing price for BTTX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Better Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BTTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BTTX

Analyst Price Target is $6.00
▲ +57,042.86% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Better Therapeutics in the last 3 months. The average price target is $6.00, with a high forecast of $9.00 and a low forecast of $3.00. The average price target represents a 57,042.86% upside from the last price of $0.01.

This chart shows the closing price for BTTX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 2 contributing investment analysts is to buy stock in Better Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/21/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/21/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/20/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/18/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/16/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/15/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/14/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/14/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/10/2023Lake Street CapitalLower TargetBuy ➝ Buy$5.00 ➝ $3.00Low
8/10/2023Chardan CapitalReiterated RatingBuy ➝ Buy$9.00N/A
4/14/2023Lake Street CapitalLower TargetBuy$6.00 ➝ $5.00Low
3/31/2023Lifesci CapitalDowngradeOutperform ➝ Market PerformLow
3/31/2023Chardan CapitalLower TargetBuy$14.00 ➝ $9.00Low
11/15/2022Chardan CapitalLower TargetBuy$17.00 ➝ $14.00Low
5/16/2022Chardan CapitalLower TargetNA$15.00Low
3/16/2022Chardan CapitalBoost TargetBuy$17.00 ➝ $18.00High
12/27/2021Lifesci CapitalReiterated RatingOutperformHigh
11/24/2021Chardan CapitalInitiated CoverageBuy$17.00High
11/10/2021CowenInitiated CoverageOutperformLow
(Data available from 7/14/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
12/17/2023
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/16/2024
  • 5 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/15/2024
  • 1 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/16/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/15/2024
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/15/2024
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/14/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/14/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Better Therapeutics logo
Better Therapeutics, Inc., a prescription digital therapeutics company, develops a form of cognitive behavioral therapy to address the causes of cardiometabolic diseases. The company's lead product candidate is BT-001, an investigational PDT platform to treat type 2 diabetes. It also develops software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions. In addition, the company's clinical development candidates are intended to treat cardiometabolic diseases, including type 2 diabetes, hypertension, hyperlipidemia, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and chronic kidney disease. Its product pipeline also includes BT-002, which intends glycemic control for hypertension; BT-003 to reduce LDL cholesterol in patients with hyperlipidemia; and BT-004, which intends to explore the impact of treatment on liver health in patients with non-alcoholic steatohepatitis/non-alcoholic fatty liver disease. The company was founded in 2015 and is headquartered in San Francisco, California.
Read More

Today's Range

Now: $0.01
Low: $0.01
High: $0.01

50 Day Range

MA: $0.01
Low: $0.01
High: $0.01

52 Week Range

Now: $0.01
Low: $0.01
High: $0.91

Volume

147,575 shs

Average Volume

455,601 shs

Market Capitalization

$523.53 thousand

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.05

Frequently Asked Questions

What sell-side analysts currently cover shares of Better Therapeutics?

The following Wall Street analysts have issued reports on Better Therapeutics in the last twelve months: Chardan Capital, and Lake Street Capital.
View the latest analyst ratings for BTTX.

What is the current price target for Better Therapeutics?

2 Wall Street analysts have set twelve-month price targets for Better Therapeutics in the last year. Their average twelve-month price target is $6.00, suggesting a possible upside of 57,042.9%. Chardan Capital has the highest price target set, predicting BTTX will reach $9.00 in the next twelve months. Lake Street Capital has the lowest price target set, forecasting a price of $3.00 for Better Therapeutics in the next year.
View the latest price targets for BTTX.

What is the current consensus analyst rating for Better Therapeutics?

Better Therapeutics currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe BTTX will outperform the market and that investors should add to their positions of Better Therapeutics.
View the latest ratings for BTTX.

What other companies compete with Better Therapeutics?

How do I contact Better Therapeutics' investor relations team?

Better Therapeutics' physical mailing address is 311 WEST 43RD STREET 12TH FLOOR, NEW YORK NY, 10036. The company's listed phone number is 415-887-2311 and its investor relations email address is [email protected]. The official website for Better Therapeutics is mcacquisition.com. Learn More about contacing Better Therapeutics investor relations.